A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices / Medical Express
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 11:21 pm / permalink 20776 / 4 stories in 45 hrs
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision / MedCity
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance
Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 2 days
Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 2 days
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up / MedCity
Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #digitalhealth #healthcarefinance #supplychain
Saturday, March 14, 2026, 2:22 pm / permalink 20763 / 3 stories in 2 days
Fitch upgrades UCHealth’s rating to ‘AA+’ / Beckers
Andrew Cass / beckershospitalreview - Aurora, Colo.-based UCHealth’s credit rating was upgraded to “AA+” from “AA” by Fitch. The upgrade reflects the health system’s very strong financial profile, benefiting from its market position in a growing service area and a long track record of robust …
#healthcare #publichealth #governmentpolicy #digitalhealth #medicaldevices #oncology #hospitaloperations #cancerresearch
Saturday, March 14, 2026, 2:22 pm / permalink 20762 / 5 stories in 2 days
Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia / OncoDaily
oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 12:23 pm / permalink 20760 / 2 stories in 2 days
The appendix evolved at least 32 times across 361 species, so it's 'unlikely to be a useless evolutionary accident,' research finds / LiveScience
livescience - Two researchers explore the evolutionary history of the appendix and its role in human health.
#healthcare #wildlife #animalhealth
Saturday, March 14, 2026, 11:22 am / permalink 20758 / 2 stories in 2 days
Personalized Support Program Improves Smoking Cessation for Cervical Cancer Survivors – UCLA Health / OncoDaily
oncodaily - UCLA study shows program doubles quit rates for women and offers a cost-effective approach A new study led by UCLA researchers suggests that a personalized counseling program can significantly help […]
#healthcare #publichealth #oncology #behavioralhealth #cancerresearch
Saturday, March 14, 2026, 6:21 am / permalink 20747 / 2 stories in 2 days
Grail names new CEO as Bob Ragusa retires / Endpoints
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
#healthcare #biotech #medicaldevices #oncology #healthcarefinance #cancerresearch
Saturday, March 14, 2026, 4:21 am / permalink 20744 / 5 stories in 2 days
Measles outbreaks could fuel rise in fatal complication, physicians warn / Beckers
Mackenzie Bean / beckershospitalreview - As measles continues spreading across the U.S. at a pace not seen in decades, physicians are warning about a rare but often fatal neurological complication that can emerge years after initial infection, KFF Health News reported March 13. Subacute sclerosi…
#healthcare #publichealth #governmentpolicy #cdc #vaccinesafety #infectiousdisease
Saturday, March 14, 2026, 2:21 am / permalink 20742 / 8 stories in 2 days
Vanderbilt Health president, CEO to retire / Beckers
Paige Twenter / beckershospitalreview - Jeff Balser, MD, PhD, president and CEO of Vanderbilt Health and dean of Vanderbilt University’s school of medicine, plans to retire from both roles Dec. 31, according to a March 12 news release from the Nashville, Tenn.-based organizations. During his 17…
#healthcare #hospitaloperations #healthcarefinance #researchfunding
Saturday, March 14, 2026, 2:21 am / permalink 20741 / 2 stories in 2 days
AMA: Physicians' use of AI doubled from 2023 to 2026 / Fierce
fiercehealthcare - A survey fielded earlier this year found 81% of doctors use AI in a professional context, with an average of 2.3 use cases per physician. Respondents were largely bullish on the technology's ability to boost clinical care and work efficiency, but still ha…
#healthcare #publichealth #governmentpolicy #digitalhealth #hospitaloperations #cybersecurity
Saturday, March 14, 2026, 1:21 am / permalink 20740 / 14 stories in 2 days
Ipsen pulls cancer drug Tazverik from market over safety risks / Endpoints
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch
Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days
Eliquis may be safer than Xarelto for patients with deep blood clots: Study / Beckers
Ella Jeffries / beckershospitalreview - Patients taking blood thinner Eliquis had a lower risk of clinically relevant bleeding than those taking Xarelto, a recent study found. Researchers enrolled 2,760 patients with venous thrombosis — blood clots in the veins of the legs or lungs — and random…
#healthcare #pharmaceuticals #publichealth #drugdevelopment
Saturday, March 14, 2026, 12:23 am / permalink 20737 / 2 stories in 2 days
Flu vaccines didn't work that well in the US, officials find / Medical Express
medicalxpress - As the U.S. flu season winds down, health officials say the flu vaccine didn't work very well, with one of its worst effectiveness rates in more than a decade.
#healthcare #pharmaceuticals #publichealth #drugdevelopment #cdc #vaccinesafety #infectiousdisease
Saturday, March 14, 2026, 12:23 am / permalink 20736 / 3 stories in 2 days
A smartphone app can help men last longer in bed / New Scientist
newscientist - In a randomised trial, men who experience premature ejaculation benefitted from using an app to learn techniques for extending intercourse
#healthcare #publichealth #digitalhealth #medicaldevices #behavioralhealth
Saturday, March 14, 2026, 12:23 am / permalink 20735 / 2 stories in 2 days